Pandemic influenza vaccines: Meeting the supply, distribution and deployment challenges

Influenza and other Respiratory Viruses

Volumn 3, Issue 4, 2009, Pages 165-170

  Hessel, Luc ^a  

^a The European Vaccine Manufacturers (EVM) Influenza Working Group   (Belgium)

Author keywords

Influenza; Infrastructure; Logistic; Pandemic; Supply; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; DRUG APPROVAL; DRUG STORAGE; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INFORMATION DISSEMINATION; MASS IMMUNIZATION; PANDEMIC; PRIORITY JOURNAL; RESOURCE ALLOCATION; STRATEGIC PLANNING; TRAINING; VACCINE PRODUCTION;

DISEASE OUTBREAKS; DRUG STORAGE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 67649105602     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2009.00085.x     Document Type: Article

References (14)

1. European Medicines Agency. Pandemrix European Public Assessment Report. Summary of Product Characteristics. 2008; Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/pandemrix/H-832-PI-en.pdf (Accessed 28 May 2009).
2. International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply International Task Force. Industry provides significant voluntary contributions to global pandemic preparations. 2008; available at http://www.ifpma.org/influenza/content/pdfs/WHO_IGM/ 2008_11_Industry_Contributions_to_Pandemic_Preparations.pdf (Accessed 28 May 2009).
3. Ehrlich H, Müller M, Oh H, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-2584.
4. Stephenson I, Bugarini R, Nicholson K et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. JID 2005; 191:1210-1215.
5. Novartis. Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu. 2008; Company press release, available at http://www.medicalnewstoday.com/ articles/123088.php (Accessed 28 May 2009).
6. GlaxoSmithKline. New data for GlaxoSmithKline's pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning. 2008; Company press release, available at http://www.medicalnewstoday.com/articles/121877.php (Accessed 28 May 2008).
7. Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 298:242-249.
8. Stephenson I, Nicholson K, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631-33.
9. The Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macroepidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 2005; 23: 5133-5143.
10. The International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply (IFPMA IVS) task force. Influenza Vaccine Distribution in 141 Countries, 2004-2007. 2008; presented at: Third European Influenza Conference. Vilamoura, Portugal, 14-17 September.
11. Hehme N, Colegate T, Palache B, Hessel L. Influenza vaccine supply: building long-term sustainability. Vaccine 2008; 26S:D23-D26.
12. Jacobson SH, Sewell EC, Jokela JA. Survey of vaccine distribution and delivery issues in the USA: From pediatrics to pandemics. Expert Rev Vaccines 2007; 6:981-990.
13. Aaby K, Abbey RL, Herrmann JW, Treadwell M, Jordan CS, Wood K. Embracing computer modelling to address pandemic influenza in the 21st Century. J Public Health Manag Pract 2006; 12:365-372.
14. US Department of Health and Human Services and US Department of Homeland Security. Guidance on allocating and targeting pandemic influenza vaccine. available at http://www.pandemicflu.gov/vaccine/ allocationguidance.pdf (accessed 12 January 2009).